BioCryst Pharmaceuticals
BCRX
109 hedge funds and large institutions have $156M invested in BioCryst Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 42 increasing their positions, 26 reducing their positions, and 27 closing their positions.
82% more call options, than puts
Call options by funds: $167K | Put options by funds: $92K
62% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 26
8% less funds holding
Funds holding: 118 → 109 (-9)
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
76% less capital invested
Capital invested by funds: $650M → $156M (-$494M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management II
New York
|
+$20.8M |
| 2 |
D.E. Shaw & Co
New York
|
+$6.59M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$3.51M |
| 4 |
VM
VHCP Management
New York
|
+$2.5M |
| 5 |
SIM
Spark Investment Management
New York
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$28.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$26.5M |
| 3 |
QF
QVT Financial
New York
|
-$14M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$11.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.74M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
126
Strategic Investment Management
Arlington,
Virginia
| – | -$116K | -11,336 | Closed |
|
|
OAM
127
Oxford Asset Management
Oxford,
United Kingdom
| – | -$110K | -10,598 | Closed |
|
|
PAM
128
Panagora Asset Management
Boston,
Massachusetts
| – | -$87K | -8,393 | Closed |
|
|
WAM
129
Wolverine Asset Management
Chicago,
Illinois
| – | -$52K | -5,100 | Closed |
|
|
TRCT
130
Tower Research Capital (TRC)
New York
| – | -$44K | -4,237 | Closed |
|
131
Walleye Trading
New York
| – | -$21K | -2,000 | Closed |
|
132
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$10K | -1,000 | Closed |
|
|
IA
133
IFP Advisors
Tampa,
Florida
| – | -$10K | -1,000 | Closed |
|
|
EFSCE
134
Enterprise Financial Services Corp (EFSC)
Clayton,
Missouri
| – | -$1K | -118 | Closed |
|
BCRX Hedge Fund Activity: Q1 2016 in Review
109 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2016, worth a combined $156M — down 76% from $650M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of BCRX and 18 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 42 added.
The largest buyer was VHCP Management II, opening a new position worth an estimated $20.8M. The largest seller was Fidelity Investments, cutting an estimated $28.8M.
- 109 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2016, down from 118 in Q4 2015.
- Funds reported $156M of BioCryst Pharmaceuticals stock for Q1 2016, down 76% quarter-over-quarter.
- 18 funds opened new BioCryst Pharmaceuticals positions in Q1 2016 and 27 closed out, a net change of -9 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2016 was VHCP Management II, an estimated $20.8M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2016 was Fidelity Investments, an estimated $28.8M sold.
Based on aggregated 13F filings for Q1 2016.